Assignee
ROCHE GLYCART AG
CH45 patents
Top patents by PatentIndex Score
US10184009B2Jan 22, 2019
Mutant interleukin-2 polypeptides
ROCHE GLYCART AG37 citations97
US9695233B2Jul 4, 2017
Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
ROCHE GLYCART AG44 citations97
US9526797B2Dec 27, 2016
Combination IL-2 immunoconjugate therapy
ROCHE GLYCART AG57 citations97
US8021856B2Sep 20, 2011
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ROCHE GLYCART AG51 citations97
US9346872B2May 24, 2016
Interleukin-10 fusion proteins
ROCHE GLYCART AG43 citations96
US11130822B2Sep 28, 2021
Immunoconjugates
ROCHE GLYCART AG16 citations94
US10577429B2Mar 3, 2020
Anti-FAP antibodies and methods of use
ROCHE GLYCART AG17 citations94
US10323098B2Jun 18, 2019
Mutant interleukin-2 polypeptides
ROCHE GLYCART AG25 citations94
US10316104B2Jun 11, 2019
Immunoconjugates
ROCHE GLYCART AG30 citations94
US10253110B2Apr 9, 2019
Anti-FAP antibodies and methods of use
ROCHE GLYCART AG15 citations94
US10202464B2Feb 12, 2019
Immunoconjugates
ROCHE GLYCART AG30 citations94
US9926379B2Mar 27, 2018
Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5
ROCHE GLYCART AG17 citations92
US9206260B2Dec 8, 2015
Anti-CEA antibodies
ROCHE GLYCART AG23 citations92
US9771427B2Sep 26, 2017
ASGPR antibodies and uses thereof
ROCHE GLYCART AG16 citations91
US11332545B2May 17, 2022
Anti-FAP antibodies and methods of use
ROCHE GLYCART AG6 citations86
US10603360B2Mar 31, 2020
Combination IL-2 immunoconjugate therapy
ROCHE GLYCART AG13 citations85
US11111312B2Sep 7, 2021
Mutant interleukin-2 polypeptides
ROCHE GLYCART AG8 citations84
US11214622B2Jan 4, 2022
Antibodies specific for DR5 and methods of use
ROCHE GLYCART AG6 citations83
US10155815B2Dec 18, 2018
Bispecific T cell activating antigen binding molecules
ROCHE GLYCART AG12 citations83
US10087250B2Oct 2, 2018
Fc-free antibodies comprising two fab-fragments and methods of use
ROCHE GLYCART AG10 citations83
US9346886B2May 24, 2016
Humanized anti-CDCP1 antibodies
ROCHE GLYCART AG8 citations83
US9309317B2Apr 12, 2016
Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
ROCHE GLYCART AG6 citations83
US10562949B2Feb 18, 2020
Interleukin-2 fusion proteins and uses thereof
ROCHE GLYCART AG6 citations82
US10040843B2Aug 7, 2018
Interleukin-10 fusion proteins and uses thereof
ROCHE GLYCART AG7 citations82
US9650442B2May 16, 2017
Bispecific anti-EGFR/anti IGF-1R antibodies
ROCHE GLYCART AG14 citations82
US8367374B2Feb 5, 2013
Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
ROCHE GLYCART AG9 citations81
US11459404B2Oct 4, 2022
Bispecific T cell activating antigen binding molecules
ROCHE GLYCART AG5 citations72
US10781258B2Sep 22, 2020
Bispecific T cell activating antigen binding molecules
ROCHE GLYCART AG4 citations72
US10683345B2Jun 16, 2020
Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
ROCHE GLYCART AG5 citations72
US9321843B2Apr 26, 2016
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ROCHE GLYCART AG3 citations72
US12286486B2Apr 29, 2025
Anti-FAP antibodies and methods of use
ROCHE GLYCART AG0 citations62
US11639397B2May 2, 2023
Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use
ROCHE GLYCART AG0 citations62
US10781257B2Sep 22, 2020
Bispecific T cell activating antigen binding molecules
ROCHE GLYCART AG1 citations62
US9611331B2Apr 4, 2017
Anti-HER3 antibodies and uses thereof
ROCHE GLYCART AG1 citations62
US10975151B2Apr 13, 2021
ASPGR antibodies and uses thereof
ROCHE GLYCART AG0 citations61
US11365232B2Jun 21, 2022
Interleukin-2 fusion proteins and uses thereof
ROCHE GLYCART AG1 citations60
US8859234B2Oct 14, 2014
Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
ROCHE GLYCART AG3 citations60
US9360481B2Jun 7, 2016
Predictive biomarker for cancer treatment with ADCC-enhanced antibodies
ROCHE GLYCART AG2 citations55
US10196456B2Feb 5, 2019
Anti-HER3 antibodies and uses thereof
ROCHE GLYCART AG0 citations51
US10087254B2Oct 2, 2018
ASPGR antibodies and uses thereof
ROCHE GLYCART AG0 citations51
US9957326B2May 1, 2018
Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
ROCHE GLYCART AG0 citations51
US9718885B2Aug 1, 2017
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ROCHE GLYCART AG0 citations51
US9631023B2Apr 25, 2017
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ROCHE GLYCART AG0 citations51
US9994610B2Jun 12, 2018
Separation method for fucosylated antibodies
ROCHE GLYCART AG0 citations50
US10352943B2Jul 16, 2019
A-fucosylation detection in antibodies
ROCHE GLYCART AG0 citations49